Brazikumab

Brazikumab (AMG 139) is a human IgG2 monoclonal antibody, selectively binds the p19 subunit of IL-23, with a KD of 0.138 nM for human IL-23. Brazikumab can be used for the research of Crohn's disease[1].

IL-23: 0.138 nM (Kd)

[1] Currò D, et, al. Frontiers in Drug Research and Development for Inflammatory Bowel Disease. Front Pharmacol. 2017 Jun 23;8:400. DOI:10.3389/fphar.2017.00400
[2] Al-Bawardy B, et, al. Novel and Emerging Therapies for Inflammatory Bowel Disease. Front Pharmacol. 2021 Apr 14;12:651415. DOI:10.3389/fphar.2021.651415